Palivizumab (Synagis); RSV Monoclonal Antibody; Inj: 50, 100 mg; 15 mg/kg IM once a month during RSV season (usually Nov-April). May not be given
IV.
AAP-approved indications: (1) <2 yrs with chronic lung disease that has required medical treatment within the past six months; (2) chronological age <1
yr at start of RSV season and gestational age <28 weeks; (3) chronological age <6 months at start of RSV season and gestational age 29-32 weeks
Not indicated for treatment of RSV
infection.